Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2020

View Archived Issues

New mouse model of MS reveals that oligodendroglia-specific connexin 47 regulates neuroinflammation

Matinas BioPharma initiates ENHANCE-IT study of MAT-9001

BioCryst initiates proof-of-concept trial of BCX-9930 in PNH

BITRAP demonstrates promising efficacy in preclinical models of rheumatoid arthritis

Servier publishes phase II data from RESTORE BRAIN study of S-44819

Phase I data for enzalutamide plus capivasertib in mCRPC

Enanta Pharmaceuticals patents MAP3K5 inhibitors

BenevolentAI Bio divulges new NTRK1 inhibitors

Blocking trash trashes MSI-hi tumors

Adlai Nortye describes hSTING receptor agonists

Il-Yang Pharmaceutical presents new antivirals

JAGUAHR Therapeutics patents new AhR antagonists

Indian approval of saroglitazar for noncirrhotic NASH

New gene fusion EWSR1-PATZ1 found in renal cell carcinoma

NCS-01 begins phase I/II study in patients with acute ischemic stroke

Enrollment open in phase I study of FT-596 for relapsed/refractory B-cell lymphoma or CLL

Gene therapy converts astrocytes into GABAergic neurons, alleviating motor deficits in HD models

Endocytosis inhibitor improves anticancer MAb efficacy

Gene rearrangements involving HMGA1/2 found in spindle cell/pleomorphic lipomas

Third cohort underway in phase I trial of Actimab-A plus CLAG-M for relapsed/refractory AML

Arcturus partners with Duke-NUS on COVID-19 vaccine development

Camrelizumab approved in China for advanced hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...